[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE249813T1 - Einhüllungssverfahren - Google Patents

Einhüllungssverfahren

Info

Publication number
ATE249813T1
ATE249813T1 AT98948005T AT98948005T ATE249813T1 AT E249813 T1 ATE249813 T1 AT E249813T1 AT 98948005 T AT98948005 T AT 98948005T AT 98948005 T AT98948005 T AT 98948005T AT E249813 T1 ATE249813 T1 AT E249813T1
Authority
AT
Austria
Prior art keywords
active substance
alternatively
phase
aqueous
biodegradable polymer
Prior art date
Application number
AT98948005T
Other languages
English (en)
Inventor
Timo Laakso
Mats Reslow
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of ATE249813T1 publication Critical patent/ATE249813T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/14—Polymerisation; cross-linking
    • B01J13/18—In situ polymerisation with all reactants being present in the same phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Surgical Instruments (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
AT98948005T 1997-10-23 1998-09-24 Einhüllungssverfahren ATE249813T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703874A SE512663C2 (sv) 1997-10-23 1997-10-23 Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
PCT/SE1998/001717 WO1999020253A1 (en) 1997-10-23 1998-09-24 Encapsulation method

Publications (1)

Publication Number Publication Date
ATE249813T1 true ATE249813T1 (de) 2003-10-15

Family

ID=20408722

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98948005T ATE249813T1 (de) 1997-10-23 1998-09-24 Einhüllungssverfahren

Country Status (19)

Country Link
US (1) US6861064B1 (de)
EP (1) EP1033973B1 (de)
JP (1) JP2001520186A (de)
KR (1) KR100572711B1 (de)
AT (1) ATE249813T1 (de)
AU (1) AU732891B2 (de)
CA (1) CA2306824C (de)
CZ (1) CZ299100B6 (de)
DE (1) DE69818295T2 (de)
DK (1) DK1033973T3 (de)
ES (1) ES2205551T3 (de)
HK (1) HK1029931A1 (de)
HU (1) HU224008B1 (de)
IL (1) IL135733A (de)
NO (1) NO310177B1 (de)
PT (1) PT1033973E (de)
SE (1) SE512663C2 (de)
WO (1) WO1999020253A1 (de)
ZA (1) ZA989199B (de)

Families Citing this family (319)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219487B (hu) 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR20010002589A (ko) * 1999-06-16 2001-01-15 김윤 생리활성물질 함유 생분해성 고분자 마이크로스피어의 제조방법
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
IT1318539B1 (it) * 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
HUP0302622A3 (en) * 2000-10-06 2006-07-28 Jagotec Ag Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
SE517422C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
JP2004510730A (ja) 2000-10-06 2004-04-08 ヤゴテック　アーゲー 非経口的投与可能な制御放出微粒子調製物
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
JP2004513706A (ja) * 2000-11-16 2004-05-13 ヤゴテック　アーゲー 微粒子の製造方法
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
KR100676266B1 (ko) * 2000-12-08 2007-01-30 주식회사 엘지생활건강 인체 세정 조성물 내에서 마이크로 스피어의 제조방법,마이크로 스피어 및 이를 함유하는 세정 조성물
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
JP2004516262A (ja) 2000-12-21 2004-06-03 ネクター セラピューティクス 親水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
EP1355666B1 (de) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von "repulsive guidance molecule" (rgm) und von dessen modulatoren
WO2002058671A1 (en) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Burst free pharmaceutical microparticules
EP1418890B1 (de) * 2001-08-16 2008-05-14 Baxter International Inc. Darreichungsformen welche mikropartikel und treibgas enthalten
US20050233945A1 (en) * 2003-07-18 2005-10-20 Larry Brown Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US7105181B2 (en) 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
KR100560068B1 (ko) * 2002-03-14 2006-03-13 주식회사 태평양 구강용 마이크로 캡슐의 제조방법 및 이 방법에 의해 제조된 마이크로 캡슐을 함유하는 구강용 조성물
SE0201599D0 (sv) 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
KR101388611B1 (ko) 2002-10-16 2014-04-23 퍼듀 퍼머 엘피 세포-연관된 ｃａ 125/ｏ772ｐ에 결합하는 항체들 및 그것의 용도의 방법들
JP4723859B2 (ja) * 2002-12-04 2011-07-13 日本曹達株式会社 Ｏｉｌ／Ｏｉｌ液中乾燥法による農薬マイクロカプセル製剤及びその製造方法
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
EP1587540B1 (de) 2003-01-09 2021-09-15 MacroGenics, Inc. Identifikation und herstellung von antikörpern mit varianten fc regionen und anwendungsverfahren dafür
JP2007525149A (ja) 2003-01-13 2007-09-06 マクロジェニクス，インコーポレーテッド 可溶性ＦｃγＲ融合タンパク質およびその使用法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2784762A1 (en) * 2003-04-10 2004-10-28 President And Fellows Of Harvard College Formation and control of fluidic species
EP2316487B1 (de) 2003-04-11 2014-06-11 MedImmune, LLC Rekombinante IL-9 Antikörper und ihre Verwendung
US7326571B2 (en) 2003-07-17 2008-02-05 Boston Scientific Scimed, Inc. Decellularized bone marrow extracellular matrix
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
BRPI0414004A (pt) 2003-08-27 2006-10-24 Harvard College controle eletrÈnico de espécies fluìdicas
JP2005138051A (ja) * 2003-11-07 2005-06-02 Kurita Water Ind Ltd 除去材の製造方法及び除去材
FR2867075B1 (fr) * 2004-03-03 2006-07-14 Ethypharm Sa Procede de preparation de microspheres biodegradables calibrees
EP1765294B1 (de) 2004-05-12 2008-09-24 Baxter International Inc. Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
PT1758558E (pt) * 2004-05-12 2013-12-05 Baxter Healthcare Sa Microesferas contendo oligonucleótidos, sua utilização para o fabrico de um medicamento para o tratamento de diabetes do tipo 1
EP1778268B1 (de) 2004-07-21 2016-05-04 Tulane University Health Sciences Center Behandlung von nierenfehlfunktion und multiplem myelom mithilfe von pacap-verbindungen
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
KR20070105331A (ko) * 2005-02-11 2007-10-30 노랩스 에이비 일산화질소를 포함하는 신경병증의 치료 장치, 방법 및용도
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
EP1871433B1 (de) 2005-03-24 2009-04-22 NOLabs AB Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2272156B1 (es) * 2005-04-18 2008-04-01 Italfarmaco, S.A. Sistemas microparticulares.
US20060260777A1 (en) * 2005-04-27 2006-11-23 Julia Rashba-Step Surface-modified microparticles and methods of forming and using the same
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
WO2007014445A1 (en) * 2005-08-02 2007-02-08 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
PT2573114T (pt) 2005-08-10 2016-07-13 Macrogenics Inc Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
EP2500358A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
KR101114659B1 (ko) * 2005-10-14 2012-03-05 (주)아모레퍼시픽 생분해성 고분자를 이용하여 유용성 활성성분을 안정화한나노입자 및 이의 제조방법
ES2524984T3 (es) 2005-11-30 2014-12-16 Abbvie Inc. Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CN1799649A (zh) * 2005-12-09 2006-07-12 清华大学 一种血液相容性生物材料及其制备方法
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
EP2198863A1 (de) 2006-02-27 2010-06-23 The Johns Hopkins University Krebsbehandlung mit gamma-sekretasehemmern
KR100722191B1 (ko) * 2006-04-19 2007-05-29 경북대학교 산학협력단 고내구성 방향성 접착제 및 이를 이용한 서방형 방향 섬유
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
AU2007260687B2 (en) 2006-06-14 2013-12-12 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
CA2657517C (en) 2006-08-04 2016-11-01 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
PL2292663T3 (pl) 2006-08-28 2014-03-31 Kyowa Hakko Kirin Co Ltd Antagonistyczne ludzkie przeciwciała monoklonalne swoiste wobec ludzkiego LIGHT
PT3207941T (pt) 2006-09-07 2020-04-02 Scott & White Memorial Hospital Métodos e composições baseados em conjugados de toxina diftérica-interleucina-3
UA115964C2 (uk) 2006-09-08 2018-01-25 Еббві Айрленд Анлімітед Компані Інтерлейкін-13-зв'язувальний білок
MX2009003661A (es) * 2006-10-06 2009-04-22 Baxter Int Microcapsulas que contienen microparticulas modificadas en la superficie y metodos para formar y utilizar las mismas.
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
EP2139458A4 (de) * 2007-04-19 2013-01-23 Dong A Pharm Co Ltd Biologisch abbaubare mikrokügelchen-zusammensetzung zur kontrollierten freisetzung von glucose-kontrollierendem peptid und formulierung daraus
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
MX2009013816A (es) 2007-06-21 2010-02-24 Macrogenics Inc Diacuerpos covalentes y usos de los mismos.
JP2010535032A (ja) 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
EP2244729B1 (de) 2008-01-18 2016-11-02 MedImmune, LLC Cystein-manipulierte antikörper zur stellenspezifischen konjugation
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8323651B2 (en) 2008-05-09 2012-12-04 Abbott Laboratories Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CN102143760B (zh) 2008-07-08 2015-06-17 Abbvie公司 前列腺素e2结合蛋白及其用途
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
WO2010039865A2 (en) * 2008-10-01 2010-04-08 Cornell University Biodegradable chemical delivery system
US20110218155A1 (en) 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
CA2746256C (en) 2008-12-09 2020-03-24 Loren D. Walensky Methods and compositions for specific modulation of mcl-1
SG10201407908VA (en) 2008-12-19 2015-01-29 Macrogenics Inc Covalent diabodies and uses thereof
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
CN105254758A (zh) 2009-03-05 2016-01-20 Abbvie公司 Il-17结合蛋白
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
ES2548030T3 (es) 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
EP2711018A1 (de) 2009-06-22 2014-03-26 MedImmune, LLC Manipulierte Fc-Regionen für standortspezifische Konjugation
SG178335A1 (en) 2009-08-13 2012-03-29 Crucell Holland Bv Antibodies against human respiratory syncytial virus (rsv) and methods of use
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486141B1 (de) 2009-10-07 2018-01-10 MacroGenics, Inc. Fc-regionshaltige polypeptide mit besserer effektorfunktion aufgrund von änderungen des ausmasses einer fukosylierung sowie verwendungsverfahren dafür
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201121568A (en) 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN102883739B (zh) 2009-11-02 2015-11-25 图兰恩教育基金管理人 垂体腺苷酸环化酶激活多肽（pacap）的类似物和它们的应用方法
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MY160628A (en) 2010-03-02 2017-03-15 Abbvie Inc Therapeutic DLL4 Binding Proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP2013527761A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
KR20130066632A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
PL2571532T3 (pl) 2010-05-14 2017-10-31 Abbvie Inc Białka wiążące IL-1
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
EP3333188B1 (de) 2010-08-19 2022-02-09 Zoetis Belgium S.A. Anti-ngf-antikörper und deren verwendung
PH12013500333A1 (en) 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
JP5714111B2 (ja) 2010-08-30 2015-05-07 ハンファ ケミカル コーポレーション 酸化鉄ナノカプセル、酸化鉄ナノカプセルの製造方法及びこれを利用したｍｒｉ造影剤
KR101642939B1 (ko) * 2010-08-31 2016-07-26 한화케미칼 주식회사 산화철 나노캡슐, 이의 제조방법 및 이를 포함하는 자기공명영상진단 조영제
US8580739B2 (en) * 2010-11-17 2013-11-12 East Carolina University Methods of reducing myocardial injury following myocardial infarction
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
SG191312A1 (en) 2010-12-21 2013-07-31 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
CN104080804B (zh) 2011-05-21 2017-06-09 宏观基因有限公司 去免疫化的血清结合结构域及其延长血清半衰期的用途
EP2729131B1 (de) 2011-07-05 2020-04-15 Novan, Inc. Topische zusammensetzungen
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
CN103906765A (zh) 2011-09-23 2014-07-02 抗菌技术生物技术研究与发展股份有限公司 抗肿瘤坏死因子-α试剂及其用途
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
CA2853258A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
WO2013083605A1 (en) * 2011-12-05 2013-06-13 Ferring Bv Triptorelin pharmaceutical composition
SG11201402739YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CA2858012C (en) 2011-12-05 2021-10-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
MX356933B (es) 2011-12-14 2018-06-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2797955A2 (de) 2011-12-30 2014-11-05 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
HUE039611T2 (hu) 2012-01-27 2019-01-28 Abbvie Deutschland Készítmények és eljárások axondegenerációval járó betegségek diagnózisára és kezelésére
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US9408419B2 (en) 2012-03-23 2016-08-09 Victoria's Secret Store Brand Management, Inc. Moisturizing fabric material, use thereof in moisturizing bras, and method of manufacture
WO2013168172A1 (en) 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
SG11201407017WA (en) 2012-06-04 2014-12-30 Irm Llc Site-specific labeling methods and molecules produced thereby
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
RU2017137740A (ru) 2012-11-01 2019-02-11 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
RU2015115956A (ru) 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
RU2015129551A (ru) 2012-12-19 2017-01-25 Эмплиммьюн, Инк. Антитела к в7-н4 человека и их применение
EP2935332B1 (de) 2012-12-21 2021-11-10 MedImmune, LLC Anti-h7cr antikörpern
HUE054443T2 (hu) 2013-02-08 2021-09-28 Novartis Ag Ellenanyagok módosítására, ezáltal immunkonjugátumok elõállítására szolgáló specifikus helyek
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3916103A1 (de) 2013-03-14 2021-12-01 Abbott Laboratories Monoklonale antikörper gegen hcv-core lipid-bindender domäne
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
EP2970479B1 (de) 2013-03-14 2019-04-24 Novartis AG Antikörper gegen notch 3
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2970459A2 (de) 2013-03-15 2016-01-20 AbbVie Inc. Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
US9789203B2 (en) 2013-03-15 2017-10-17 Novartis Ag cKIT antibody drug conjugates
US10316092B2 (en) 2013-05-24 2019-06-11 The John Hopkins University Anti-B7-H5 antibodies and their uses
EP3003390B1 (de) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54-antikörper und verwendungen davon
CA2914566A1 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
ES2836132T3 (es) 2013-08-08 2021-06-24 Novan Inc Composiciones tópicas y métodos de uso de las mismas
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP3044236A2 (de) 2013-09-12 2016-07-20 Halozyme, Inc. Modifizierte anti-egfr-antikörper und verfahren zur verwendung davon
JP2016533318A (ja) 2013-09-17 2016-10-27 ユニバーシティ ヘルス ネットワーク （ユーエイチエヌ）： テクノロジー ディベロップメント アンド コマーシャリゼーション Ｒｇｍａ／ネオジェニンのシス相互作用又は脂質ラフトを標的とする剤及び治療方法における該剤の使用
WO2015058868A1 (en) 2013-10-25 2015-04-30 Pangaea Biotech, S.L. Compositions and methods for the treatment of cancer
WO2015066480A1 (en) 2013-11-01 2015-05-07 Regents Of The University Of Minnesota Protein scaffolds and methods of use
BR112016009797A2 (pt) 2013-11-13 2017-12-05 Bristol Myers Squibb Co anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
TW201536320A (zh) 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2015123241A1 (en) 2014-02-14 2015-08-20 Chi Andrew S Improved methods for the treatment of vascularizing cancers
JP6870988B2 (ja) 2014-02-24 2021-05-19 セルジーン コーポレイション 神経細胞増幅及び中枢神経系障害治療のためのセレブロンの活性化因子の使用方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
EP3960767A3 (de) 2014-03-12 2022-06-01 Novartis AG Spezifische stellen zur modifizierung von antikörper zur herstellung von immunkonjugaten
EP3126006A1 (de) 2014-03-21 2017-02-08 AbbVie Inc. Anti-egfr-antikörper und antikörperwirkstoffkonjugate
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
MX2016015479A (es) 2014-05-29 2017-03-23 Macrogenics Inc Moleculas de union tri-especificas que se unen especificamente a varios antigenos de cancer y metodos de uso de los mismos.
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3539990B1 (de) 2014-07-16 2021-09-08 Dana-Farber Cancer Institute, Inc. Her3-inhibition bei serösem low-grade ovarialkarzinom
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
CN105813617B (zh) 2014-08-08 2021-05-28 诺万公司 局部用组合物和使用所述组合物的方法
AP2017009719A0 (en) 2014-08-12 2017-01-31 Novartis Ag Anti-cdh6 antibody drug conjugates
MA40573A (fr) 2014-09-26 2016-03-31 Macrogenics Inc Anticorps dimériques monovalents bispécifiques à région capables de se lier à cd19 et à cd3 et leurs utilisations
TN2017000173A1 (en) 2014-11-14 2018-10-19 Novartis Ag Antibody drug conjugates
MX2017007303A (es) 2014-12-04 2017-08-25 Novartis Ag Metodos y composiciones que utilizan polipeptidos variantes klotho.
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US20160244520A1 (en) 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
WO2016122702A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
TW201632202A (zh) 2015-01-30 2016-09-16 諾華公司 乳癌之治療
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
SI3303395T1 (sl) 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3310813A1 (de) 2015-06-17 2018-04-25 Novartis AG Antikörper-wirkstoff-konjugate
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
PL3456346T3 (pl) 2015-07-30 2021-12-20 Macrogenics, Inc. Cząsteczki wiążące pd-1 i lag-3 oraz sposoby ich zastosowania
BR112018004867A2 (pt) 2015-09-11 2018-10-16 Abbvie Deutschland métodos para tratamento das formas recorrentes de esclerose múltipla
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
EP3365369A1 (de) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2-antikörper sowie zusammensetzungen und verwendungen davon
JP7090545B2 (ja) 2015-12-02 2022-06-24 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
AR107781A1 (es) 2015-12-14 2018-06-06 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
EP3423100A4 (de) 2016-03-02 2019-10-16 Novan, Inc. Zusammensetzungen zur behandlung von entzündungen und verfahren zur behandlung davon
EP3442502A4 (de) 2016-04-13 2019-11-06 Novan, Inc. Zusammensetzungen, systeme, kits und verfahren zur behandlung von infektionen
WO2017192407A1 (en) 2016-05-02 2017-11-09 Roman Bielski Microcapsules for controlled delivery of an active pharmaceutical ingredient
UY37278A (es) 2016-06-08 2018-01-31 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
BR112018075653A2 (pt) 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco
CA3029622A1 (en) 2016-07-01 2018-01-04 Dana-Farber Cancer Institute, Inc. Compositions, assays, and methods for direct modulation of fatty acid metabolism
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
EP3515943A4 (de) 2016-09-19 2020-05-06 Celgene Corporation Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
CA3036701A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3544628A4 (de) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1bb-bindende proteine und verwendungen davon
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US11260358B2 (en) * 2017-04-17 2022-03-01 The Trustees Of The University Of Pennsylvania Aqueous systems of at least two phases containing microcapsules and processes for manufacturing the same
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
PE20210554A1 (es) 2017-12-01 2021-03-17 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
CA3093772C (en) 2018-03-12 2024-04-16 Zoetis Services Llc Anti-ngf antibodies and methods thereof
EP3774863A1 (de) 2018-03-29 2021-02-17 Pfizer Inc Lfa3-varianten sowie zusammensetzungen und verwendungen davon
US10640576B2 (en) 2018-04-10 2020-05-05 Y-Biologics Inc. Cell engaging binding molecules
JP7490574B2 (ja) 2018-05-31 2024-05-27 ノバルティス アーゲー Ｂ型肝炎抗体
CR20200571A (es) 2018-06-01 2021-01-18 Novartis Ag Moléculas de únion contra bcma y usos de las mismas
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
CN112823167A (zh) 2018-09-07 2021-05-18 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
MX2021003393A (es) 2018-09-27 2021-05-13 Celgene Corp Proteinas de fijacion a sirp alfa y metodos de uso de estas.
JP2022504682A (ja) * 2018-10-12 2022-01-13 ユニバーシティ オブ ワシントン 患者の体から尿毒症毒素を除去するシステム及び方法
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
EP4406555A3 (de) 2018-12-21 2024-11-06 Novartis AG Antikörper gegen pmel17 und konjugate davon
CN113557228B (zh) 2019-03-08 2024-12-31 阿比蒂斯有限公司 位点特异性的抗体偶联和作为其具体实例的抗体-药物偶联物
TW202102526A (zh) 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 重組腺相關病毒及其用途
US20230042103A1 (en) 2019-07-26 2023-02-09 Regenxbio Inc. Engineered nucleic acid regulatory element and methods of uses thereof
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
EP4041768A1 (de) 2019-10-09 2022-08-17 StCube & Co. Spezifische antikörper gegen glykosiertes lag3 und verfahren zur verwendung davon
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN115461363A (zh) 2020-05-01 2022-12-09 诺华股份有限公司 免疫球蛋白变体
EP4143236A1 (de) 2020-05-01 2023-03-08 Novartis AG Manipulierte immunglobuline
KR20230025005A (ko) 2020-06-17 2023-02-21 얀센 바이오테크 인코포레이티드 만능 줄기세포의 제조를 위한 재료 및 방법
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
KR102228138B1 (ko) * 2020-08-11 2021-03-17 (주)바이오제닉스 향 오일을 포함하는 마이크로캡슐의 제조방법, 이의 방법으로 제조된 향 오일을 함유하는 마이크로캡슐 및 이를 포함하는 분산액
WO2022076750A2 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Recombinant adeno-associated viruses for cns or muscle delivery
MX2023003699A (es) 2020-10-07 2023-04-21 Regenxbio Inc Virus adenoasociados para el suministro ocular de genoterapia.
JP2023547506A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
EP4240491A1 (de) 2020-11-06 2023-09-13 Novartis AG Cd19-bindende moleküle und verwendungen davon
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022258829A1 (en) 2021-04-16 2023-10-26 Novartis Ag Antibody drug conjugates and methods for making thereof
EP4373506A1 (de) 2021-07-20 2024-05-29 AGS Therapeutics SAS Extrazelluläre vesikel aus mikroalgen, ihre herstellung und verwendungen
EP4413019A2 (de) 2021-10-07 2024-08-14 RegenxBio Inc. Rekombinante adeno-assoziierte viren zur zns-tropen verabreichung
US20250001006A1 (en) 2021-10-07 2025-01-02 Regenxbio Inc. Recombinant adeno-associated viruses for targeted delivery
WO2023077092A1 (en) 2021-10-28 2023-05-04 Regenxbio Inc. Engineered nucleic acid regulatory elements and methods and uses thereof
US20250011428A1 (en) 2021-10-28 2025-01-09 Novartis Ag Engineered fc variants
EP4460517A1 (de) 2022-01-07 2024-11-13 Johnson & Johnson Enterprise Innovation Inc. Materialien und verfahren für il-1beta-bindende proteine
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
EP4475884A1 (de) 2022-02-09 2024-12-18 Janssen Biotech, Inc. Verfahren und zusammensetzungen mit v-beta-17-bispezifischen t-zell-engagern und biotechnologisch hergestellten virusspezifischen lymphozyten
WO2023178053A1 (en) 2022-03-13 2023-09-21 Regenxbio Inc. Modified muscle-specific promoters
EP4507741A1 (de) 2022-04-14 2025-02-19 RegenxBio Inc. Gentherapie zur behandlung einer augenerkrankung
WO2023201277A1 (en) 2022-04-14 2023-10-19 Regenxbio Inc. Recombinant adeno-associated viruses for cns tropic delivery
WO2023205610A2 (en) 2022-04-18 2023-10-26 Regenxbio Inc. Hybrid aav capsids
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors
WO2024044725A2 (en) 2022-08-24 2024-02-29 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
WO2024081746A2 (en) 2022-10-11 2024-04-18 Regenxbio Inc. Engineered nucleic acid regulatory elements and methods and uses thereof
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024182767A1 (en) 2023-03-01 2024-09-06 Provention Bio, Inc. Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil
WO2024194423A1 (en) 2023-03-23 2024-09-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their use for vaccines and for immunomodulation
WO2024206739A1 (en) 2023-03-30 2024-10-03 Provention Bio, Inc. Methods for reducing exogenous insulin use
WO2024216244A2 (en) 2023-04-13 2024-10-17 Regenxbio Inc. Targeting aav capsids, methods of manufacturing and using same
WO2024238853A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Adeno-associated viruses for ocular delivery of gene therapy
WO2025024848A1 (en) 2023-07-27 2025-01-30 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
CH660302A5 (fr) 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
JP2582186B2 (ja) * 1989-05-04 1997-02-19 サウザン リサーチ インスティチュート カプセル封じ法及びその製品
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
PT674506E (pt) 1992-12-02 2001-01-31 Alkermes Inc Microsferas contendo hormona de crescimento com libertacao controlada
DE69426292T2 (de) 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
US5578709A (en) 1993-03-09 1996-11-26 Middlesex Sciences, Inc. Macromolecular microparticles and methods of production
ATE197398T1 (de) 1994-09-09 2000-11-11 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
CA2223583A1 (en) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics Inc. Device for releasing aggregation-stabilized, biologically active agent

Also Published As

Publication number Publication date
PT1033973E (pt) 2004-02-27
ZA989199B (en) 1999-04-15
IL135733A (en) 2005-11-20
HUP0004732A3 (en) 2001-12-28
NO20002039L (no) 2000-06-13
AU9467098A (en) 1999-05-10
IL135733A0 (en) 2001-05-20
KR100572711B1 (ko) 2006-04-24
AU732891B2 (en) 2001-05-03
SE512663C2 (sv) 2000-04-17
HUP0004732A2 (hu) 2001-05-28
EP1033973A1 (de) 2000-09-13
HU224008B1 (hu) 2005-04-28
DE69818295D1 (de) 2003-10-23
KR20010031289A (ko) 2001-04-16
ES2205551T3 (es) 2004-05-01
EP1033973B1 (de) 2003-09-17
DK1033973T3 (da) 2004-02-02
WO1999020253A1 (en) 1999-04-29
HK1029931A1 (en) 2001-04-20
NO310177B1 (no) 2001-06-05
CZ299100B6 (cs) 2008-04-23
NO20002039D0 (no) 2000-04-18
US6861064B1 (en) 2005-03-01
CZ20001352A3 (cs) 2000-10-11
CA2306824C (en) 2008-01-08
JP2001520186A (ja) 2001-10-30
SE9703874L (sv) 1999-04-24
DE69818295T2 (de) 2004-07-08
CA2306824A1 (en) 1999-04-29
SE9703874D0 (sv) 1997-10-23

Similar Documents

Publication Publication Date Title
ATE249813T1 (de) Einhüllungssverfahren
BRPI0115730B8 (pt) método de preparação de um material compreendendo um polímero hidrofílico, anfótero ou aniônico que possui atividade antimicrobiana
DK1131152T3 (da) Fremgangsmåde til fremstilling af mikroindkapslede formuleringer
ES8707424A1 (es) Un procedimiento para encapsular un compuesto organico cuya solubilidad es mayor en un primer disolvente que en un se- gundo disolvente
CY1107059T1 (el) Υδατικη διασπορα που περιεχει σταθερα νανοσωματιδια μιας αδιαλυτης στο νερο δραστικης ουσιας κι ενα εκδοχο οπως τα τριγλυκεριδια μεσης αλυσιδας (mct)
DE60107872D1 (de) Herstellung von wirkstoffpartikeln durch evaporation-präzipitation in wässrige lösungen
JP2001520186A5 (de)
PT720471E (pt) Microparticulas polimericas hidrofobas
NO982364D0 (no) FremgangsmÕte for fremstilling av morfologisk anhetlige mikrokapsler, samt mikrokapsler fremstilt ved fremgangsmÕten
DK0709085T3 (da) Depotpræparat
CA2391660A1 (en) Responsive polymeric hollow particles
DE60104340D1 (de) Verfahren zur Herstellung von wirkstofbeladenen Polymer-Micellen Zusammensetzung
DE60222734D1 (de) Mikropartikel und Verfahren zur deren Herstellung
ES2178268T3 (es) Formulaciones de liberacion controlada.
AR032386A1 (es) Preparaciones de ciclodextrina
ATE353922T1 (de) Verfahren zur herstellung von vergrösserten latexteilchen
ATE556788T1 (de) Herstellung pharmazeutischer wirkstoffpartikel unter verwendung fokussierter akustischer energie
DK1196148T3 (da) Proces til mikroindkapsling af vand-opløselige stoffer
AR124969A1 (es) Nuevas microcápsulas que contienen sustancias activas
DK1061948T3 (da) Præparat til vedvarende frigivelse af et fysiologisk aktivt polypeptid samt fremstilling deraf
ATE388689T1 (de) Verwendung von wirkstoffmischungen mit azelainsäure und glycyrrhetinsäure als anti- aknemittel
AR046065A1 (es) Cristales de penam y procedimiento para la produccion de los mismos
AR062374A1 (es) Metodo para prevenir la cristalizacion
Wang et al. Recent Progress of Fuel‐Driven Temporary Materials
DE50211163D1 (de) Mikrokapseln mit Anti-Aknewirkstoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1033973

Country of ref document: EP

REN Ceased due to non-payment of the annual fee